Date: 2016-09-28
Type of information: Collaboration agreement
Compound: ANAVEX2-73 (tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride)
Company: Anavex Life Sciences (USA - NY) Biogen (USA - MA)
Therapeutic area: Neurological diseases - CNS diseases
Type agreement: collaboration materiel transfert agreement
Action mechanism: Anavex2-73 is an agonist of the intracellular sigma-1 chaperone protein. The compound is a mixed muscarinic receptor/sigma 1 ligand. It has been reported to have memory-preserving and neuroprotective effects in mice treated with the muscarinic receptor antagonist scopolamine, with synthetic ABêta oligomer injection, or with the NMDA receptor agonist dizocilpine. A recent study suggested that Anavex 2-73 may block tau hyperphosphorylation.
Disease:
Details: * On September 28, 2016, Anavex Life Sciences announced that it has signed a material transfer agreement with Biogen under which Biogen will test Anavex’s lead drug candidate, ANAVEX 2-73 in an oligodendrocyte precursor cell (OPC) differentiation assay. A satisfactory result from the OPC assay study may lead to an in vivo remyelination study using a chemical demyelination model. “Battling demyelinating diseases such as multiple sclerosis requires an understanding of the processes that cause remyelination to fail. Remyelination of demyelinated axons is typically a function of oligodendrocyte precursor cells. These studies will examine the therapeutic role ANAVEX 2-73 may play in permitting remyelination in the brain,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.
Financial terms:
Latest news:
